George Mulligan, PhD, highlights the importance of clinical trials and innovative research in advancing myeloma treatment and pursuing potential cures.
George Mulligan, PhD
Advertisement
George Mulligan, PhD, is the chief scientific officer of the Multiple Myeloma Research Foundation (MMRF).
Articles by George Mulligan, PhD
George Mulligan, PhD, explores the impact of linvoseltamab's FDA approval on multiple myeloma treatment, highlighting innovative bispecific antibodies and patient-centered strategies.
George Mulligan, PhD, discusses the ODAC's review of daratumumab for high-risk smoldering multiple myeloma, noting its efficacy in delaying progression but raising questions about patient criteria.
Following the FDA ODAC's vote against belantamab mafodotin-based combinations in relapsed/refractory multiple myeloma, George Mulligan, PhD, provides insight into the agent's potential path foward.
George Mulligan, PhD, previews the FDA's ODAC meeting discussing the application of belantamab mafodotin-based combinations for the treatment of multiple myeloma.
Advertisement
Latest Updated Articles
Linvoseltamab Ushers in a New Era in Myeloma TreatmentPublished: September 3rd 2025 | Updated:
- Will Belantamab Mafodotin Get a Second Chance at Approval in Multiple Myeloma?
Published: July 16th 2025 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
Safusidenib Shows Robust, Ongoing Responses in Grade 2 IDH1-Mutant Glioma
4
Sac-TMT Demonstrates Antitumor Activity, Safety in Urothelial Carcinoma
5
